Gland Pharma Limited has informed the Exchange regarding a press release dated November 03, 2025, titled "Press release on Q2FY26 Financial Results".
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gland Pharma reported consolidated revenue of ₹14,869 crore in Q2 FY26, up 6% year-on-year, with PAT rising 12% to ₹1,837 crore. For the first half of FY26, revenue grew 7% to ₹29,925 crore while PAT jumped 30% to ₹3,992 crore. Adjusted EBITDA margin expanded by 150 basis points year-on-year for the quarter and 370 basis points for the half year, reaching 23% in H1 FY26. USA revenue grew 10%, Europe 16%, and the European subsidiary Cenexi saw a 21% revenue increase although it remained in negative EBITDA due to a planned shutdown. The company launched 7 new molecules in the USA, filed 6 ANDAs, and is expanding GLP-1/pen/cartridge capacity from 40 million to 140 million units.
Strong half-yearly performance with 30% PAT growth and meaningful margin expansion signals healthy operating leverage and execution on cost improvements. Sequential decline in quarterly numbers (revenue -1%, PAT -15% QoQ) and continued losses at Cenexi are minor concerns, but management's outlook remains positive with new launches and capacity expansion expected to drive H2 momentum.